Cisco's next quarterly call, which will reflect our fiscal year 2025 third-quarter results, will be on Wednesday, May 14, ...

Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting ...

Palatin Technologies, Inc. (AMEX: PTN) Q2 2025 Earnings Call Transcript February 13, 2025 ...

The Company's Board of Directors (the "Board”) approved payment of the $0.0075 per share per month dividend beginning in ...

Q2 2025 Earnings Call Transcript February 12, 2025 Aytu BioPharma, Inc. beats earnings expectations. Reported EPS is $-0.26, ...

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ...

Q2 2025 Earnings Call Transcript February 6, 2025 Operator: Good day, everyone, and welcome to Lumentum Holdings Second ...

H1 2024-25 results in line with expectations Operating verticals revenues of €600m up 3.9% like-for-like1 Adjusted EBITDA margin of 55.2% FY 2024-25 objectives confirmed ...

Good morning, and welcome to the Conference Call for Tate & Lyle's Q3 Trading Statement. Your speakers today are Nick Hampton, Chief Executive; and Sarah Kuijlaars, Chief Financial Officer. I will now ...

Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater ...

NeuroOne Medical Technologies Corporation ( NASDAQ: NMTC) Q1 2025 Earnings Conference Call February 12, 2025 8:30 AM ET ...

Operator: Greetings, and welcome to the Great Elm Group Fiscal 2025 Second Quarter Conference Call. At this time, all ...